biostudies-literatureRen XJean Perkins FoundationNIDCR NIH HHSNational Institute of Dental and Craniofacial ResearchNIGMS NIH HHSNational Science Foundation213262https://www.ebi.ac.uk/biostudies/studies/S-EPMC10089592biostudies-literatureUnknown145Custom synthesis of extracellular matrix (ECM)-inspired materials for condition-specific reconstruction has emerged as a potentially translatable regenerative strategy. In skull defect reconstruction, nanoparticulate mineralized collagen glycosaminoglycan scaffolds (MC-GAG) have demonstrated osteogenic and anti-osteoclastogenic properties, culminating in the ability to partially heal in vivo skull defects without the addition of exogenous growth factors or progenitor cell loading. In an effort to reduce catabolism during early skull regeneration, we fabricated a composite material (MCGO) of MC-GAG and recombinant osteoprotegerin (OPG), an endogenous anti-osteoclastogenic decoy receptor. In the presence of differentiating osteoprogenitors, MCGO demonstrated an additive effect with endogenouBiomaterials advancesOsteoprotegerin-eluting nanoparticulate mineralized collagen scaffolds improve skull regeneration.PMC10089592R01 DE028098T32 GM070421R01 DE029234R01 DE030491Ren XLee JCHuang KXChan CHZhou QHarley BACDahan NJBedar MKolliopoulos VDejam DOberoi MKDewey MJfalseOsteoprotegerin-eluting nanoparticulate mineralized collagen scaffolds improve skull regeneration.Custom synthesis of extracellular matrix (ECM)-inspired materials for condition-specific reconstruction has emerged as a potentially translatable regenerative strategy. In skull defect reconstruction, nanoparticulate mineralized collagen glycosaminoglycan scaffolds (MC-GAG) have demonstrated osteogenic and anti-osteoclastogenic properties, culminating in the ability to partially heal in vivo skull defects without the addition of exogenous growth factors or progenitor cell loading. In an effort to reduce catabolism during early skull regeneration, we fabricated a composite material (MCGO) of MC-GAG and recombinant osteoprotegerin (OPG), an endogenous anti-osteoclastogenic decoy receptor. In the presence of differentiating osteoprogenitors, MCGO demonstrated an additive effect with endogenou2023-01-01T00:00:00Z2023 Feb2025-07-12T03:04:25.04Z2025-04-06T13:22:27.037ZS-EPMC100895923656566910.1016/j.bioadv.2022.213262